Published in Sci Rep on May 15, 2014
The LRIG family: enigmatic regulators of growth factor receptor signaling. Endocr Relat Cancer (2014) 0.86
Novel strategy for a bispecific antibody: induction of dual target internalization and degradation. Oncogene (2016) 0.77
The Endosome-associated Deubiquitinating Enzyme USP8 Regulates BACE1 Enzyme Ubiquitination and Degradation. J Biol Chem (2016) 0.76
USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability. Oncogene (2016) 0.75
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
The emerging shape of the ESCRT machinery. Nat Rev Mol Cell Biol (2007) 6.05
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov (2008) 4.76
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
Targeting the c-Met signaling pathway in cancer. Clin Cancer Res (2006) 3.57
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene (2004) 3.27
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J (1991) 3.20
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res (2009) 3.11
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature (2002) 2.99
Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes. Mol Biol Cell (2005) 2.31
A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol (2011) 2.11
The UIM domain of Hrs couples receptor sorting to vesicle formation. J Cell Sci (2003) 1.97
Invasive growth: from development to metastasis. J Clin Invest (2002) 1.91
UBPY: a growth-regulated human ubiquitin isopeptidase. EMBO J (1998) 1.76
LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol (2006) 1.55
Targeting ubiquitin specific proteases for drug discovery. Biochimie (2007) 1.45
LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer (2007) 1.44
Deubiquitinating enzymes as novel anticancer targets. Future Oncol (2007) 1.43
GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Dev Cell (2011) 1.31
The Hrs/STAM complex in the downregulation of receptor tyrosine kinases. J Biochem (2005) 1.27
Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. J Cell Biol (1994) 1.22
Scatter factors and invasive growth. Semin Cancer Biol (2001) 1.21
MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett (2008) 1.08
Regulation of epidermal growth factor receptor ubiquitination and trafficking by the USP8·STAM complex. J Biol Chem (2010) 1.08
USP8 is a novel target for overcoming gefitinib resistance in lung cancer. Clin Cancer Res (2013) 1.04
Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody. Oncogene (2012) 1.01
ERBB2 is a target for USP8-mediated deubiquitination. Cell Signal (2010) 1.00
"Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res (2008) 0.97
Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest (2010) 0.96
A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer. Mol Cells (2012) 0.88
Lrig1: a new master regulator of epithelial stem cells. EMBO J (2012) 0.82